Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor α subtype-selective activators

Journal of Medicinal Chemistry

Volumn 46, Issue 17, 2003, Pages 3581-3599

  Nomura, Masahiro ^a   Tanase, Takahiro ^a   Ide, Tomohiro ^a   Tsunoda, Masaki ^a   Suzuki, Masahiro ^a   Uchiki, Hideharu ^a   Murakami, Koji ^a   Miyachi, Hiroyuki ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BENZENE DERIVATIVE; BEZAFIBRATE; CARBOXYL GROUP; CLOFIBRATE; FENOFIBRATE; ICOSAPENTAENOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; MALE; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CHOLESTEROL; CRICETINAE; FATTY ACIDS, NONESTERIFIED; HUMANS; MALE; MODELS, MOLECULAR; PHENYLPROPIONATES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0042732947     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205144     Document Type: Article

References (39)

1. Staels, B.; Auwerx, J. Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones. Curr. Pharm. Des. 1997, 3, 1-14.
2. Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M. Convergence of 9-cis Retinoic Acid and Peroxisome Proliferator Signalling Pathways through Heterodimer Formation of Their Receptors. Nature (London) 1992, 358, 771-774.
3. Keller, H.; Dreyer, C.; Medin, J.; Mahoudi, A.; Ozato, K.; Wahli, W. Fatty Acids and Retinoids Control Lipid Metabolism through Activation of Peroxisome Proliferator-Activated Receptor-Retinoid X Receptor Heterodimers. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 2160-2164.
4. Isseman, I.; Green, S. Activation of a Member of the Steroid Hormone Receptor Superfamily by Peroxisome Proliferators. Nature (London) 1990, 347, 645-650.
5. Lee, S. S.; Pineau, T.; Drago, J.; Lee, E. L.; Owens, J. W.; Kroetz, D. L.; Fernandez-Salguero, P. M.; Westphal, H.; Gonzalez, F. J. Targeted Disruption of the Alpha Isoform of the Peroxisome Proliferator-Activated Receptor Gene in Mice Results in Abolishment of the Pleiotropic Effects of Peroxisome Proliferators. Mol. Cell. Biol. 1995, 15, 3012-22.
6. Aoyama, T.; Peters, J. M.; Iritani, N.; Nakajima, T.; Furihata, K.; Hashimoto, T.; Gonzalez, F. J. Altered Constitutive Expression of Fatty Acid-Metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-Activated Receptor Alpha (PPARalpha). J. Biol. Chem. 1998, 273, 5678-5684.
7. Linton, M. F.; Fazio, S. Re-Emergence of Fibrates in the Management of Dyslipidemia and Cardiovascular Risk. Curr. Atheroscler. Rep. 2000, 2, 29-35.
8. Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic Drugs, Polyunsaturated Fatty Acids, and Eicosanoids Are Ligands for Peroxisome Proliferator-Activated Receptors Alpha and Delta. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4312-4317.
9. (a) Nomura, M.; Takahashi, Y.; Tanase, T.; Miyachi, H.; Ide, T.; Tsunoda, M.; Murakami, K. Substituted Phenylpropanoic Acid Derivatives. PCT Int. Appl. WO 00/75103, 2000.
10. (b) Miyachi, H.; Nomura, M.; Tanase, T.; Takahashi, Y.; Ide, T.; Tsunoda, M.; Murakami, K.; Awano, K. Design, Synthesis and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Peroxisome Proliferator-Activated Receptor (PPAR) Activators: Novel Human PPARalpha-selective Activators. Bioorg. Med. Chem. Lett. 2002, 12, 77-80.
11. (c) Miyachi, H.; Nomura, M.; Tanase, T.; Suzuki, M.; Murakami, K.; Awano, K. Enantio-dependent Binding and Transactivation of Optically Active Phenylpropanoic Acid Derivatives at Human Peroxisome Proliferator-Activated Receptor Alpha. Bioorg. Med. Chem. Lett. 2002, 12, 333-335.
12. (a) Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; Akanuma, Y.; Yazaki, Y.; Kadowaki, T. A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats. Diabetes 1998, 47, 1841-1847.
13. (b) Nomura, M.; Satoh, H.; Kinoshita, M.; Maeda, M.; Tsunoda, M.; Murakami, K.; Miyachi, M.; Awano, K. (3-Substituted benzyl)-thiazolidine-2,4-diones as Structurally New Antihyperglycemic Agents. Bioorg. Med. Chem. Lett. 1998, 8, 533-538.
14. Yoshioka, T.; Fujita, T.; Kanai, T.; Aizawa, Y.; Kurumada, T.; Hasegawa, K.; Horikoshi, H. Studies on Hindered Phenols and Analogues. 1. Hypolipidemic and Hypoglycemic Agents with Ability To Inhibit Lipid Peroxidation. J. Med. Chem. 1989, 32, 421-428.
15. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
16. Cantello, B. C. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The Synthesis of BRL-49653-A Novel Potent Antihyperglycemic Agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-1184.
17. Lehmann, J. M.; Moore, L. B.; Smith-oliver, T. A.; Wilkinson, W. O.; Willson, T. M.; Kliewer, S. A. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor Gamma (PPAR gamma). J. Biol. Chem. 1995, 270, 12953-12956.
18. Grieco, P. A.; Handy, S. T. Magnesium Trifluoromethanesulfonamide (Triflimide) Promoted Substitution Reactions of Allylic and Benzylic Acetates. Magnesium Triflimide as a Substitute for Magnesium Perchorate. Tetrahedron Lett. 1997, 38, 2645-2648.
19. Rondestvedt, C. S. Arylation of Unsaturated Compounds by Diazonium Salts (The Meerwein Arylation Reaction). Org. React. 1976, 24, 225-259.
20. Haigh, D.; Birrell, H. C.; Cantello, B. C. C.; Hindley, R. M.; Ramaswamy, A.; Rami, H. K.; Stevens, N. C. Non-Thiazolidinedione Antihyperglycemic Agents Part 4: Synthesis of Racemic, (R)-(+)- and (S)-(-)-Enantiomers of 2-Oxy-3-arylpropanoic Acids. Tetrahedron: Asymmetry 1999, 10, 1335-1351.
21. HPLC analysis was performed on a CHIRAPAC OD column (0.0046 m × 0.25 m, flow rate 1.00 mL/min, UV 254 nm, n-hexane/i-PrOH/TFA = 95:5:0.2 v/v/v as the eluant).
22. Meyers, A. I.; Knaus, G.; Kamata, K.; Ford, M. E. Asymmetric Synthesis of R and S α-Alkylalkanoic Acids from Metalation and Alkylation of Chiral 2-Oxazolines. J. Am. Chem. Soc. 1976, 98, 567-576.
23. Nomura, M.; Tanase, T.; Miyachi, H. Efficient Asymmetric Synthesis of (S)-2-Ethylphenylpropanoic Acid Derivative, a Selective Agonist for Human Peroxisome Proliferator-Activated Receptor Alpha. Bioorg. Med. Chem. Lett. 2002, 12, 2101-2104.
24. Evans, D. A.; Ennis, M. D.; Mathre, D. J. Asymmetric alkylation reaction of chiral imide enolates. A practical approach to the enantioselective synthesis of α-substituted carboxylic acid derivatives. J. Am. Chem. Soc. 1982, 104, 1737-1739.
25. Willson, T. M.; Brown, T. J.; Sternbach, D. D.; Henke, B. R. The PPARs: from Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527-550.
26. Recently, several non-thiazolidine-2,4-dione PPARγ agonists have been reported. (a) Young, P. W.; Buckle, D. R.; Cantello, B. C. C.; Chapman, H. ; Clapham, J. C.; Coyle, P. J.; Haigh, D.; Hindley, R. M.; Holder, J. C.; Kallender, H.; Latter, A. J.; Lawrie, K. W. N.; Mossakowska, D.; Murphy, G. J.; Cox, L. R.; Smith, S. A. Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ. J. Pharmacol. Exp. Ther. 1998, 284, 751. (b) Henke, B. R.; Branchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A., Jr.; Noble, S. A.; Oliver, W., Jr.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzyloxyphenyl) -L-tyrosine PPARγ Agonists. 1. Discovery of A Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
27. Recently, several non-thiazolidine-2,4-dione PPARγ agonists have been reported. (a) Young, P. W.; Buckle, D. R.; Cantello, B. C. C.; Chapman, H. ; Clapham, J. C.; Coyle, P. J.; Haigh, D.; Hindley, R. M.; Holder, J. C.; Kallender, H.; Latter, A. J.; Lawrie, K. W. N.; Mossakowska, D.; Murphy, G. J.; Cox, L. R.; Smith, S. A. Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ. J. Pharmacol. Exp. Ther. 1998, 284, 751. (b) Henke, B. R.; Branchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W., Jr.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A., Jr.; Noble, S. A.; Oliver, W., Jr.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzyloxyphenyl) -L-tyrosine PPARγ Agonists. 1. Discovery of A Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
28. Nolte, C.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand Binding and Co-activator Assembly of the Peroxisome Proliferator-Activated Receptor γ. Nature (London) 1998, 395, 137-143.
29. Buckle, D. R.; Cantello, C. C.; Cawthorne, M. A.; Coyle, P. J.; Dean, D. K.; Faller, A.; Haigh, D.; Hindley, R. M.; Jefcott, L. J.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Smith, D. G.; Smith, S. A. Non Thiazolidinedione Antihyperglycemic Agents. 1: α-Heteroatom Substituted β-Phenylpropanoic Acid. Bioorg. Med. Chem. Lett. 1996, 6, 2121-2126.
30. Gampe, R. T.; Montana, V. G.; Lambert, M. H.; Millar, A. B.; Bledsoe, R. K.; Milburn, M. V.; Kliever, S. A.; Willson, T. M.; Xu, H. E. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors. Mol. Cell 2000, 5, 545-555.
31. Cronet, P.; Petersen, J. F. W.; Folmer, R.; Blomberg, N.; Sjoeblom, K.; Karlsson, U.; Lindstedt, E. L.; Bamberg, K. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ-242; Ligand Selectivity and Agonist Activation in the PPAR Family. Structure 2001, 9, 699-706.
32. Molecular calculation and visualization were done on a Silicon Graphics O2/R10000 workstation using the software package Insight 2, version 98.0/Discover 3 from Accelrys Inc., San Diego, CA (http://www.accelrys.com).
33. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Parks, D. J.; Blanchard, S. G.; Brown, P. J.; Srtrnbach, D. D.; Lehmann, J. M.; Wisely, G. B.; Willson, T. M.; Kliever, S. A.; Milburn, M. V. Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. Mol. Cell 1999, 3, 397-403.
34. Oliver, W. R.; Shenk, J. L.; Snaith, M. R.; Russell, C. S.; Plunket, K. D.; Bodkin, N. L.; Lewis, M. C.; Wineger, D. A.; Sznaidman, M. L.; Lambert, M. H.; Xu, H. E.; Sternbach, D. D.; Kliewer, S. A.; Hansen, B. C.; Willson, T. M. A Selective Peroxisome Proliferator-Activated Receptor δ Agonist Promotes Reverse Cholesterol Transport. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5306-5311.
35. Hulin, B.; Newton, L. S.; Lewis, D. M.; Generux, P. E.; Gibbs, E. M.; Clark, D. A. Hypoglycemic Activity of a Series of α-Alkylthio and α-Alkoxy Carboxylic Acids Related to Ciglitazone. J. Med. Chem. 1996, 39, 3897-3907.
36. Parks, D. J.; Tomkinson, N. C. O.; Villeneuve, M. S.; Blanchard, S. G; Willson, T. M. Differential Activity of Rosiglitazone Enantiomers at PPARγ. Bioorg. Med. Chem. Lett. 1998, 8, 3657-3658.
37. Sohda, T.; Mizuno, K.; Kawamatsu, Y. Studies on Antidiabetic Agents 6. Asymmetric Transformation of 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (Ciglitazone) with Optically Active 1-Phenethylamines. Chem. Pharm. Bull. 1984, 32, 4460-4465.
38. Keller, H.; Devchand, P. R.; Perround, M.; Wali, W. PPARα Structure-Function Relationships Derived from Species-Specific Differences in Responsiveness to Hypolipidemic Agents. Biol. Chem. 1997, 378, 651-655.
39. Brown, P. J.; Wineger, D. A.; Plunket, K. D.; Moor, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Coble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M. A Ureidoothioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity. J. Med. Chem. 1999, 42, 3785-3788.